Patterson and co-workers have also shown that CYP1A1, as one of several CYPs, contributes in the conversion of the hypoxia-activated prodrug AQ4N to the topoisomerase II inhibitor AQ4 (Figure 2D), which has shown promise in a phase I trial that included six breast cancer patients [46,47]. Here, CYP1A1 is linked to breast cancer.